The global burden of cancer has increased significantly over the past decade, with 17.2 million new cases and 8.9 million deaths reported in 2016. Cancer control planning and implementation are crucial to fulfill global commitments for cancer control and noncommunicable diseases.
The study found that matching targeted therapies to tumor-specific gene mutations improved progression-free and overall survival in patients with advanced disease. Receiving matched targeted therapy was also an independent factor for predicting longer overall survival.
Researchers at Dana-Farber Cancer Institute have developed a blood test that can detect early-stage lung cancer using genome sequencing. The test, which analyzes free-floating DNA in the blood, has shown promise in detecting lung cancer with a low rate of false positives.
A new fossil study reveals that tiny babies of ancient giant predators were also proficient killers, challenging current understanding of their evolution. The discovery sheds light on the rapid evolution of the first animals over half-a-billion years ago, with implications for Cambrian marine food webs.
The study reveals a universal increase in lifestyle-related cancers between 2006 and 2016, with significant disparities persisting between high- and low-Socio-demographic Index countries. Breast cancer is the leading cause of cancer death in women, while lung cancer tops the list for men, accounting for nearly 20% of global cancer deaths.
A phase 1 trial of ivosidenib against IDH1+ acute myeloid leukemia (AML) achieved an overall response rate of 41.9% and median progression-free survival of 8.2 months. Twenty-four percent of patients reached a complete response.
A Phase I trial shows ivosidenib, a protein inhibitor drug, is safe and effective for treating acute myeloid leukemia (AML) patients with IDH1 mutations. The study achieved an overall response rate of 41.6% and complete remission rates of 21.6%, with improved survival rates at 18 months compared to historical controls.